Lonigutamab provides an insulin-like growth factor 1 receptor (IGF-1R)-targeting monoclonal antibody for receptor signaling and autoimmune disease research. Also known as VRDN-001, it binds IGF-1R and inhibits receptor activation. This investigational antibody specifically supports studies of thyroid eye disease (TED), IGF-1R signaling, and antibody-mediated receptor inhibition.
Key Features and Benefits
- IGF-1R-Targeting Antibody: Recognizes insulin-like growth factor 1 receptor, a cell-surface receptor specifically involved in growth and survival signaling.
- Monoclonal Antibody Design: Provides a fully human monoclonal antibody specifically for studying selective IGF-1R recognition and receptor inhibition.
- IGF-1R Signaling Inhibition: Supports investigation of antibody-mediated inhibition of IGF-1R activation and downstream signaling pathways.
- Thyroid Eye Disease Research: Enables studies of IGF-1R involvement in orbital tissue inflammation and remodeling associated with TED.
- Receptor Binding: Supports investigation of antibody-receptor interactions, target engagement, and receptor-mediated cellular responses.
- Fibroblast Signaling Research: Useful for studying IGF-1R-associated signaling in orbital fibroblasts and relevant cellular models.
- VRDN-001 Research Platform: Provides an investigational antibody platform specifically for evaluating IGF-1R-targeted therapeutic strategies.
Applications
- Thyroid Eye Disease Research: Supports investigation of IGF-1R-mediated mechanisms in thyroid eye disease models.
- Graves’ Orbitopathy Research: Useful for studying receptor signaling and cellular responses associated with Graves’ orbitopathy.
- IGF-1R Signaling Research: Supports evaluation of IGF-1R activation, inhibition, and downstream signaling pathways.
- Autoimmune Disease Research: Useful for investigating IGF-1R-associated mechanisms in relevant autoimmune disease models.
- Orbital Fibroblast Research: Supports studies of fibroblast activation, signaling, and tissue remodeling associated with TED.
- Antibody Research: Enables investigation of monoclonal antibody binding, receptor recognition, and target engagement.
- Cell-Based Receptor Assays: Useful for evaluating IGF-1R-dependent signaling and antibody-mediated receptor inhibition.
- Mechanism-of-Action Studies: Supports investigation of IGF-1R blockade and associated cellular responses.
- Comparative Antibody Research: Useful for comparing IGF-1R-targeting antibodies and receptor inhibition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Lonigutamab provides a fully human IGF-1R-targeting monoclonal antibody for investigating receptor inhibition and downstream signaling and specifically supports thyroid eye disease, Graves’ orbitopathy, orbital fibroblast, and antibody research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
